François Lamarche

François Lamarche

Auto-generated profile, based on publicly available information

François Lamarche

Department of Medical Oncology, University Hospital, Limoges 87042, France

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
VSVincent Sol
Vincent Sol
FLFrançois Lamarche
François Lamarche
MEMichaela Enache
Michaela Enache
GGGuillaume Garcia
Guillaume Garcia
RGRobert Granet
Robert Granet
PKPierre Krausz
Pierre Krausz

3 August 2007 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
MMMathieu Mével
Mathieu Mével
TMTristan Montier
Tristan Montier
FLFrançois Lamarche
François Lamarche
PDPascal Delépine
Pascal Delépine
TGTony Le Gall
Tony Le Gall
JCJean-Claude Clément
Jean-Claude Clément

1 August 2004 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
VSVincent Sol
Vincent Sol
PBP Branland
P Branland
CVChaleix Vincent
Chaleix Vincent
RGR Granet
R Granet
MGM Guilloton
M Guilloton
PKP Krausz
P Krausz

3 August 2007 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
FLFrançois Lamarche
François Lamarche
MMMathieu Mével
Mathieu Mével
TMTristan Montier
Tristan Montier
LBLaure Burel-Deschamps
Laure Burel-Deschamps
PGPhilippe Giamarchi
Philippe Giamarchi
JCJean-Claude Clément
Jean-Claude Clément

1 February 2002 in Journal of Porphyrins and Phthalocyanines
Verified
Journal Article
Closed access
FLFrançois Lamarche
François Lamarche
VSVincent Sol
Vincent Sol
YHYi-Ming Huang
Yi-Ming Huang
RGRobert Granet
Robert Granet
MGMichel Guilloton
Michel Guilloton
PKPierre Krausz
Pierre Krausz

1 January 2019 in Journal of Geriatric Oncology
Verified
Journal Article
Open access
EDelise deluche
elise deluche
SLSophie Leobon
Sophie Leobon
FLFrancois Lamarche
Francois Lamarche
NTNicole Tubiana-Mathieu
Nicole Tubiana-Mathieu
Management of glioblastoma, with a very poor prognosis, remains a challenge in older patients because of coexisting comorbidities and the increased risk of toxic treatment effects. The use of screening tools to identify vulnerable patients is essential. This study was performed to establish whether the G8 scale can be used for screening older patients with glioblastoma. We retrospectively reviewed the files of patients assessed by the G8 scale and diagnosed with glioblastoma at a single center from January 2010 to July 2017. Patients aged 65 years or older were classified into three groups (more efficiently than two groups) according to their G8 score to identify those with a poor prognosis: high score group, G8 score 14.5-17; intermediate score group, G8 score 10.5-14; and low score group, G8 score < 10.5. Of 89 patients, 19% were classified into the high score group, 43% into the intermediate score group, and 38% into the low score group. Median overall survival was four months in the low score group, 15 months in the intermediate score group, and 42 months in the high score group (p < .0001). On multivariate analysis, G8 score was a significant independent predictor of overall survival (hazard ratio: 55.46; 99.5% confidence interval: 13.42-229.13; p < .0001). Here, we highlighted the possibility of using the G8 score, with possibly three cut-offs, in the management of older patients with glioblastoma and determined the prognostic role of this quick and easy screening tool.